How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,367 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

remove one or more studies before adding more. Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02663609 Recruitment Status : Completed First Posted : January 26, 2016 Last Update Posted (...) : November 30, 2018 Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Condition or disease Intervention/treatment Cushing's Syndrome Other: No intervention Detailed Description: A retrospective, multi-center, chart review study

2016 Clinical Trials

62. Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

Evaluation of Osilodrostat in Cushing's Disease (LINC-4) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02697734 Recruitment Status : Recruiting First Posted : March 3, 2016 Last Update Posted : September 25, 2018 See Sponsor (...) : Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: Purpose of study is to aim to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy Condition or disease Intervention/treatment Phase Cushing's Disease Drug: osilodrostat Drug: osilodrostat Placebo Phase 3 Study Design Go to Layout table for study information

2016 Clinical Trials

63. Cabergoline for Cushing's disease: a large retrospective multicenter study. (PubMed)

Cabergoline for Cushing's disease: a large retrospective multicenter study. The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD.We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals.Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers (...) during the first year of treatment with cabergoline at 1.0 mg/week (0.5-3.5).About 20-25% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline.© 2017 European Society of Endocrinology.

Full Text available with Trip Pro

2016 European Journal of Endocrinology

64. Vascular health in patients in remission of Cushing's syndrome is comparable to that in BMI-matched controls. (PubMed)

Vascular health in patients in remission of Cushing's syndrome is comparable to that in BMI-matched controls. In active Cushing's syndrome (CS), patients suffer from endothelial dysfunction and premature atherosclerosis. However, it is uncertain to what extent vascular health recovers after long-term remission. This is highly relevant because this topic relates to future development of cardiovascular disease.The objective of the study was to investigate whether micro- and macrovascular health (...) ), endothelium-dependent and -independent vasodilatation was studied in conduit arteries (flow mediated dilation of the brachial artery) and forearm skeletal muscle resistance arteries (vasodilator response to intraarterial acetylcholine, sodium-nitroprusside, and NG-monomethyl-L-arginine using venous occlusion plethysmography).There were no significant differences between the outcome measures of vascular health of patients and controls in groups A and B.The vascular health of patients in long-term remission

Full Text available with Trip Pro

2016 Journal of Clinical Endocrinology and Metabolism

65. Unmasking sarcoidosis following surgery for Cushing disease (PubMed)

of underlying sarcoidosis was substantiated by lung imaging and elevated plasma interleukin (IL)-2 receptor. One month later, the lesions spontaneously resolved without therapy other than maintenance glucocorticoid replacement. Physicians should be aware that patients undergoing successful treatment of Cushing syndrome may have a flare-up or emergence of a corticosteroid-responsive disease. (...) Unmasking sarcoidosis following surgery for Cushing disease We present a patient with Cushing disease apparently suppressing sarcoidosis, which was unmasked following surgical resection of a pituitary adrenocorticotropin (ACTH)-producing microadenoma. Case report and a short review of the literature published in this area. A 46-year-old Caucasian woman presented with symptoms of hypercortisolism such as progressive weight gain, Cushingoid appearance, proximal myopathy, easy bruising

Full Text available with Trip Pro

2016 Dermato-endocrinology

66. The desmopressin test predicts better than basal cortisol the long-term surgical outcome of Cushing's disease. (PubMed)

The desmopressin test predicts better than basal cortisol the long-term surgical outcome of Cushing's disease. Cushing's disease (CD) has a significant relapse rate after successful transsphenoidal surgery (TSS). Many CD patients respond aberrantly to the desmopressin test (DT). Disappearance of this response after surgery may suggest complete removal of abnormal corticotrophs and a lower possibility of recurrence.The utility of postoperative DT to predict long-term outcome compared (...) a sensitivity of 97% to detect remission. Comparison of Kaplan-Meier curves showed that ΔCort <7.4 μg/dL was associated with remission, whereas ΔCort ≥7.4 μg/dL had a hazard ratio of recurrence of 24.7 (95% confidence interval, 10.6-448.5) at 60 months (median).Loss of desmopressin response indicates favorable prognosis and, if used in addition to basal cortisol levels, improves the accuracy of the postoperative assessment of CD.

Full Text available with Trip Pro

2016 Journal of Clinical Endocrinology and Metabolism

67. Cushing's syndrome. (PubMed)

Cushing's syndrome. Chronic exposure to excess glucorticoids results in diverse manifestations of Cushing's syndrome, including debilitating morbidities and increased mortality. Genetic and molecular mechanisms responsible for excess cortisol secretion by primary adrenal lesions and adrenocorticotropic hormone (ACTH) secretion from corticotroph or ectopic tumours have been identified. New biochemical and imaging diagnostic approaches and progress in surgical and radiotherapy techniques have

2015 Lancet

68. The Cortisol Awakening Response (CAR) is blunted in patients with active Cushing's disease. (PubMed)

The Cortisol Awakening Response (CAR) is blunted in patients with active Cushing's disease. Cortisol awakening response (CAR) is a rapid increase of cortisol levels within 30-45 min after awakening.This study evaluates CAR compared with cortisol circadian rhythm in active and in remission Cushing's disease (CD).We evaluated healthy controls (HC, n=19), obese (OB, n=10), in remission (n=08), and active CD patients (n=10). Salivary free cortisol (SF) was determined at 0800, 1100, 1700, 2000

Full Text available with Trip Pro

2013 European Journal of Endocrinology

69. Systemic vascular responses to increased intracranial pressure: 2 The `Cushing' response in the presence of intracranial space-occupying lesions: systemic and cerebral haemodynamic studies in the dog and the baboon (PubMed)

Systemic vascular responses to increased intracranial pressure: 2 The `Cushing' response in the presence of intracranial space-occupying lesions: systemic and cerebral haemodynamic studies in the dog and the baboon Continued expansion of an artificial space-occupying lesion produced further increases in mean supratentorial and infratentorial pressures associated with increases in mean arterial pressure, heart rate, and systemic vascular resistance-the `Cushing' or systemic hypertensive response (...) . These primary changes resulted in an increase in transtentorial pressure gradient and a decrease in arrhythmia index. Immediately before the onset of the systemic hypertensive response, supratentorial perfusion pressure was low, and the period of systemic hypertension did not appear to produce any worthwhile improvement in the perfusion pressure or in the blood flow in the supratentorial compartment. The studies demonstrated also that the systemic hypertensive response was a pre-terminal event

Full Text available with Trip Pro

1977 Journal of neurology, neurosurgery, and psychiatry

70. Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects

studies (100). Please remove one or more studies before adding more. Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02574793 Recruitment Status : Completed First Posted : October 14, 2015 (...) Last Update Posted : January 23, 2018 Sponsor: Huashan Hospital Information provided by (Responsible Party): xiaolong zhao, Huashan Hospital Study Details Study Description Go to Brief Summary: Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation. People with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome are at risk of impaired glucose metabolism. Glycemic variability is poorly

2015 Clinical Trials

71. Cushing's Disease Complications

Cushing's Disease Complications Cushing's Disease Complications - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cushing's Disease Complications (COMPLICUSHING) The safety and scientific validity (...) of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02568982 Recruitment Status : Recruiting First Posted : October 6, 2015 Last Update Posted : March 19, 2018 See Sponsor: Assistance Publique - Hôpitaux de Paris Information provided by (Responsible Party): Assistance

2015 Clinical Trials

72. Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease

. Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease (MEMOCUSH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02603653 Recruitment Status : Unknown Verified November 2015 by Institut National de la Santé Et de la Recherche Médicale, France. Recruitment status was: Not yet (...) recruiting First Posted : November 13, 2015 Last Update Posted : November 13, 2015 Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Information provided by (Responsible Party): Institut National de la Santé Et de la Recherche Médicale, France Study Details Study Description Go to Brief Summary: Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality. Recent studies have pinpointed

2015 Clinical Trials

73. Hippocampal volume and cognitive function in patients with Cushing's disease.ÿ A systematic review and meta-analysis of observational studies

Hippocampal volume and cognitive function in patients with Cushing's disease.ÿ A systematic review and meta-analysis of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

74. Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors

(100). Please remove one or more studies before adding more. Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors (AVS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier (...) : NCT02543697 Recruitment Status : Recruiting First Posted : September 7, 2015 Last Update Posted : September 8, 2016 See Sponsor: Haukeland University Hospital Information provided by (Responsible Party): Haukeland University Hospital Study Details Study Description Go to Brief Summary: Patients with tumors in both adrenal glands and slightly elevated cortisol (subclinical Cushings syndrome) are offered to go through an adrenal venous sampling to try to quantify if the overproduction of cortisol is from

2015 Clinical Trials

75. The role of gene mutation in Cushing disease (CD): a systematic review

The role of gene mutation in Cushing disease (CD): a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

76. Improvement and normalization of quality of life and cognitive functioning after surgical treatment for Cushing's syndrome: a systematic review and meta-analysis

Improvement and normalization of quality of life and cognitive functioning after surgical treatment for Cushing's syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

77. Cushing syndrome due to ACTH-secreting pheochromocytoma aggravated by a glucocorticoid-driven positive-feedback loop. (PubMed)

Cushing syndrome due to ACTH-secreting pheochromocytoma aggravated by a glucocorticoid-driven positive-feedback loop. Pheochromocytoma is a catecholamine-producing tumor that originates from adrenal chromaffin cells and is capable of secreting various hormones, including ACTH.A 56-year-old female presented with Cushingoid appearance and diabetic ketoacidosis. Endocrinological examinations demonstrated ectopic ACTH production with hypercortisolemia and excess urinary cortisol accompanied (...) by elevated plasma and urine catecholamines. Computed tomography revealed a large left adrenal tumor with bilateral adrenal enlargement. Metaiodobenzylguanidine scintigraphy revealed abnormal accumulation in the tumor, which was eventually diagnosed as pheochromocytoma with ectopic ACTH secretion with subsequent manifestation of Cushing's syndrome. Ectopic ACTH secretion and catecholamine production were blocked by metyrapone treatment, whereas dexamethasone paradoxically increased ACTH secretion. Left

Full Text available with Trip Pro

2015 Journal of Clinical Endocrinology and Metabolism

78. Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

and Safety of Osilodrostat in Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02468193 Recruitment Status : Completed First Posted : June 10, 2015 Last Update Posted : December 10, 2018 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis (...) Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of Efficacy

2015 Clinical Trials

79. Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease

. Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02484755 Recruitment Status : Unknown Verified June 2015 by Zhaoyun Zhang, Huashan Hospital. Recruitment status was: Recruiting First Posted : June 30, 2015 Last Update Posted (...) : June 30, 2015 Sponsor: Huashan Hospital Information provided by (Responsible Party): Zhaoyun Zhang, Huashan Hospital Study Details Study Description Go to Brief Summary: The USP8 gene and its downstream target, epidermal growth factor receptor (EGFR), is a potential therapeutic target of Cushing disease. The EGFR inhibitor, Gefitinib, has been shown to reduce the production of ACTH both in vitro and in vivo, especially in USP8-mutated corticotrophin adenomas. The investigators hypothesize

2015 Clinical Trials

80. The effects of cabergoline monotherapy in Cushing's disease: a meta-analysis

The effects of cabergoline monotherapy in Cushing's disease: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>